Depression and Anxiety in Parkinson's Disease

This is an archived file of a live webcast that took place on June 16, 2016.

In this webinar we discuss the Parkinson's symptoms of depression and anxiety, and how to treat and manage this aspect of life with the disease.

This event is part of the MJFF Third Thursdays Webinar series. Visit www.michaeljfox.org/webinars for more information and to view past webinars.

Title: Depression and Anxiety in Parkinson's Disease

Duration: 1 hour

Continuing Medical Education Information for Health Care Professionals

Continuing Medical Education Information
MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

Date of Original Release: June 16, 2016
Date CME Credit No Longer Available: June 16, 2018

Learning Objectives

At the conclusion of this course, participants should be able to:

  • Recognize the impact of depression and anxiety in Parkinson's disease.
  • Identify the symptoms of depression and anxiety in Parkinson's.
  • Discuss the underlying causes (both psychological and neurochemical factors) of depression and anxiety in Parkinson's disease.
  • Summarize the current medication treatments of depression and anxiety in Parkinson's disease as well as strategies for patients and family members to manage symptoms.
  • Describe ongoing research efforts into depression and anxiety in Parkinson's disease and why these endeavors are important.

Target Audience
This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Oakstone Publishing, LLC and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for 1.0 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure
Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing, LLC's planners, content reviewers, and editorial staff disclose no relevant commercial interests.

Faculty
Laura Marsh, MD
Executive Director of the Mental Health Service
Michael E. DeBakey Veterans Affairs Medical Center, Houston
No disclosures

Gregory Pontone, MD
Director, Parkinson's Neuropsychiatry Clinical Programs
Johns Hopkins University School of Medicine
Disclosures: Expert Testimony to Allergan Inc., Material Support from UCB (drug rotigotine and placebo supplied for NIH-funded study)
Dave Iverson
Founding Member, MJFF Patient Council
No disclosures

Register

Already Registered?

*Required Fields.

You must have Javascript and Cookies enabled to access this webcast. Click here for Help.